Anixa Biosciences wins Australian patent for breast cancer vaccine

Anixa Biosciences received an Australian composition-of-matter patent covering its breast cancer vaccine through 2040, complementing IP in the U.S., Europe, China and Japan. The company says a Phase 1 trial met primary endpoints and showed immune responses in over 74% of participants.